A systematic review” by J. García-Mina et al., published in the Journal of Clinical Rheumatology: Practical Reports on Rheumatic & Musculoskeletal Diseases (Vol. 11, Issue 3, July-August 2025)
Osteogenesis Imperfecta (OI) is a rare genetic disorder that causes bones to be fragile and break easily, often accompanied by other symptoms like blue eye sclera, hearing loss, and short stature. While scientists have identified over 20 different genes linked to the condition, about 90% of cases are caused by mutations in the COL1A1 or COL1A2 genes, which are responsible for producing Type I collagen. Researchers in Estonia recently took advantage of their small population to study the genetic makeup of nearly 100% of the OI families in their country, providing a rare and complete “snapshot” of the disease.
By analyzing 30 unrelated patients, the study found that 87% of them carried a mutation in their collagen genes. This matches the patterns seen in nearby Northern European countries like Finland and Sweden. Interestingly, half of the mutations discovered were “novel,” meaning they had never been recorded in global genetic databases before. This highlights just how unique the genetic blueprint of OI can be from one family to the next.
The researchers also looked at how these mutations affect the body. Most patients (roughly 69%) had quantitative mutations, which means their bodies simply don’t produce enough collagen. Others had qualitative mutations, where the body produces “bad” collagen that doesn’t work correctly; the most frequent error in this group was the substitution of the amino acid Glycine with Serine.
One of the most intriguing parts of the study was the “mystery” of how the same mutation affects people differently. For example, two unrelated patients were found to have the exact same genetic mutation, yet one had a mild form of OI (Type I) while the other had a much more severe form (Type III). This suggests that genetics are only part of the story, and other factors like environment or epigenetics may influence how severe the symptoms become.
To understand how collagen functions in the bone, think of it as the steel rebar inside a concrete pillar. If there isn’t enough steel (a quantitative defect), the pillar is weak; if the steel is bent or rusted (a qualitative defect), the pillar becomes brittle and prone to snapping under pressure.
What this may mean for OI Patients
For patients and families, this research is a reminder that genetics is not a simple “yes or no” diagnosis. The fact that the same mutation can lead to different levels of severity shows that there may be other “protective factors” at play that keep some people’s symptoms milder than others. Additionally, the discovery of so many novel mutations emphasizes the importance of personalized genetic testing, as it helps doctors build a more complete global library of the disease, eventually leading to better-tailored treatments and a clearer understanding of how OI is inherited.